- Home
- ECO vs OPK Comparison
ECO vs OPK Comparison
Compare ECO & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECO | OPK |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | ECO | OPK |
|---|---|---|
| Price | $33.60 | $1.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $37.00 | $2.28 |
| AVG Volume (30 Days) | 260.8K | ★ 4.1M |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | $349,886,578.00 | ★ $642,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | $14.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.91 | $1.11 |
| 52 Week High | $39.77 | $2.04 |
Technical Indicators
Market Signals| Indicator | ECO | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 46.12 | 50.24 |
| Support Level | $31.75 | $1.24 |
| Resistance Level | $33.89 | $1.33 |
| Average True Range (ATR) | 0.84 | 0.05 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 42.81 | 57.14 |
Price Performance
Historical ComparisonAbout ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.